麴菌病市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按藥物類型、按給藥途徑、按配銷通路、按地區和競爭進行細分，2020-2030 年

2024 年全球曲霉病市場價值為 46.3 億美元，預計到 2030 年將達到 58.7 億美元，預測期內年複合成長率(CAGR) 為 4.02%。該市場是醫療保健產業不可或缺的一部分，專注於解決曲霉菌相關真菌感染帶來的挑戰。曲霉菌病是由曲霉菌引起的一組疾病，其中侵襲性曲霉病是最嚴重的形式，主要影響免疫系統較弱的個體，例如器官移植接受者和接受化療的患者。市場涵蓋了廣泛的診斷、治療和預防解決方案，旨在管理和對抗這些感染。

市場成長的主要驅動力是免疫功能低下人群的日益增多，這主要得益於愛滋病毒/愛滋病發病率的上升、器官移植以及免疫抑制療法的廣泛使用。這導致對先進診斷工具的需求激增，包括 PCR 檢測、抗原檢測和 CT 掃描等影像技術，這些技術可實現早期發現和及時治療。

關鍵市場促進因素

免疫功能低下患者發生率上升

主要市場挑戰

認知有限和診斷不足

主要市場趨勢

免疫調節療法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球麴菌病市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（慢性肺部麴菌病、過敏性支氣管肺麴菌病 (ABPA)、侵襲性麴菌病）
  • 依藥物類型（艾沙康唑、伏立康​​唑、兩性黴素 B、伊曲康唑、皮質類固醇、泊沙康唑、其他）
  • 依給藥途徑（口服、靜脈注射）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按類型
  • 依藥物類型
  • 依給藥途徑
  • 按配銷通路
  • 按地區

第5章：亞太麴菌病市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型
  • 依藥物類型
  • 依給藥途徑
  • 按配銷通路
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第6章：歐洲麴菌病市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第7章：北美麴菌病市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 類型
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第8章：南美曲霉菌病市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第9章：中東和非洲麴菌病市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 12 章：全球麴菌病市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Pfizer Inc.
• Therma Fisher Scientific
• Rewine Pharmaceuticals
• Teva Pharmaceuticals
• Eugia Pharma
• krishlar Pharmaceuticals
• Merck KGA
• Aozeal
• Hikma
• Xellia Pharmaceuticals

第 15 章：策略建議

第16章調查會社について,免責事項

Global Aspergillosis Market was valued at USD 4.63 billion in 2024 and is projected to reach USD 5.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.02% during the forecast period. This market is an integral part of the healthcare sector, focusing on addressing the challenges posed by Aspergillus-related fungal infections. Aspergillosis is a group of diseases caused by the Aspergillus species, with invasive aspergillosis being the most severe form, predominantly affecting individuals with weakened immune systems, such as organ transplant recipients and patients undergoing chemotherapy. The market encompasses a broad range of diagnostic, therapeutic, and preventive solutions designed to manage and combat these infections.

A primary driver of market growth is the increasing prevalence of immunocompromised individuals, fueled by rising rates of HIV/AIDS, organ transplants, and the expanded use of immunosuppressive therapies. This has led to a surge in demand for advanced diagnostic tools, including PCR assays, antigen testing, and imaging techniques such as CT scans, which enable early detection and prompt treatment.

Key Market Drivers

Rising Incidence of Immunocompromised Patients

The growth of the global aspergillosis market is significantly influenced by the rising number of immunocompromised patients. Individuals with conditions such as HIV/AIDS, those undergoing organ transplants, and patients receiving immunosuppressive therapies are particularly vulnerable to Aspergillus-related infections. In 2023, approximately 39.9 million people globally were living with HIV, with 1.3 million new infections reported that year. In the United States, an estimated 3% of adults are immunocompromised due to immune-affecting conditions or treatments. Additionally, 172,409 organ transplants were conducted worldwide in 2023, a 9.5% increase from the previous year. These statistics underscore the growing population of immunocompromised individuals, driving demand for diagnostics and treatments for infections like aspergillosis.

Studies also show that immunocompromised patients face a heightened risk of severe infections, including those caused by SARS-CoV-2, highlighting the need for specialized care and preventive strategies. This trend emphasizes the need for tailored therapies and enhanced healthcare infrastructure to meet the unique needs of these patients, further propelling market expansion in the aspergillosis sector.

Key Market Challenges

Limited Awareness and Underdiagnosis

A significant challenge faced by the global aspergillosis market is the lack of awareness and underdiagnosis of Aspergillus-related infections. Despite the severe health risks associated with aspergillosis, it remains relatively unknown outside specialized medical circles. Many healthcare professionals, and the general public, are unfamiliar with the symptoms and risks of this fungal infection, which can often mimic other respiratory conditions, leading to misdiagnosis or delays in diagnosis. This lack of timely diagnosis can result in suboptimal or incorrect treatment, affecting patient outcomes and hindering market growth.

Furthermore, underdiagnosis-an issue stemming from limited awareness-poses a serious concern. Without early intervention, aspergillosis can progress from a treatable condition to a life-threatening disease, particularly in immunocompromised individuals. The absence of widespread educational campaigns means that high-risk populations, such as organ transplant recipients or those undergoing immunosuppressive therapies, may not receive proper screening or information. These challenges create missed opportunities for market development and the timely delivery of critical treatments.

Key Market Trends

Immunomodulatory Therapies

Immunomodulatory therapies are emerging as a key growth driver in the global aspergillosis market. These therapies, designed to modulate and enhance the immune response, offer a promising adjunctive approach to managing aspergillosis, particularly in immunocompromised individuals. For patients with weakened immune systems-such as transplant recipients, chemotherapy patients, and those with underlying immunodeficiencies-the risk of invasive aspergillosis is significantly elevated. Immunomodulatory agents like granulocyte colony-stimulating factors (G-CSF) and interferon-gamma are being studied for their potential to stimulate the immune system and help patients better combat fungal infections.

Clinical trials have demonstrated that immunomodulatory therapies, when used alongside traditional antifungal treatments, can significantly improve patient outcomes by enhancing immune function. These therapies not only aid in controlling current infections but also reduce the risk of recurrence, which is a common concern in aspergillosis management. As the benefits of immunomodulatory therapies become increasingly recognized, healthcare providers are incorporating them into treatment regimens, stimulating further market growth as pharmaceutical companies invest in developing targeted therapies tailored to the needs of aspergillosis patients.

Key Market Players

• Pfizer Inc
• Therma Fisher Scientific
• Rewine Pharmaceuticals
• Teva Pharmaceuticals
• Eugia Pharma
• krishlar Pharmaceuticals
• Merck KGA
• Aozeal
• Hikma
• Xellia Pharmaceuticals

Report Scope:

In this report, the Global Aspergillosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Aspergillosis Market, By Type:

• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Invasive Aspergillosis

Aspergillosis Market, By Drug Type:

• Isavuconazole
• Voriconazole
• Amphotericin-B
• Itraconazole
• Corticosteroids
• Posaconazole
• Others

Aspergillosis Market, By Route of Administration:

• Oral
• Intravenous

Aspergillosis Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Aspergillosis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Aspergillosis Market.

Available Customizations:

Global Aspergillosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Aspergillosis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Invasive Aspergillosis)
  • 4.2.2. By Drug Type (Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, Others)
  • 4.2.3. By Route of Administration (Oral, Intravenous)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Type
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Aspergillosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Type
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Aspergillosis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Type
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Aspergillosis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Type
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Aspergillosis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Type
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Aspergillosis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Type
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Aspergillosis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Type
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Aspergillosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Aspergillosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Aspergillosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Aspergillosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Aspergillosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Type
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Aspergillosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Type
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Aspergillosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Aspergillosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Aspergillosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Aspergillosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Aspergillosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Aspergillosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Aspergillosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Aspergillosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Aspergillosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Aspergillosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Aspergillosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Aspergillosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Aspergillosis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Pfizer Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Therma Fisher Scientific
• 14.3. Rewine Pharmaceuticals
• 14.4. Teva Pharmaceuticals
• 14.5. Eugia Pharma
• 14.6. krishlar Pharmaceuticals
• 14.7. Merck KGA
• 14.8. Aozeal
• 14.9. Hikma
• 14.10. Xellia Pharmaceuticals

15. Strategic Recommendations

16. About Us & Disclaimer